Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) trial

American Heart Journal

Volumn 161, Issue 2, 2011, Pages 391-396

  Hakim, Diaa A ^a   Dangas, George D ^b   Caixeta, Adriano ^a   Nikolsky, Eugenia ^a   Lansky, Alexandra J ^c   Moses, Jeffrey W ^a   Claessen, Bimmer ^a   Sanidas, Elias ^a   White, Harvey D ^d   Ohman, E Magnus ^e   Manoukian, Steven V ^f   Fahy, Martin ^a   Mehran, Roxana ^b   Stone, Gregg W ^a  

^a Department of Medicine   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c YALE UNIVERSITY MEDICAL CENTER   (United States)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; HEPARIN; HIRULOG;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGRAPHY; ANGIOPLASTY; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HEMATOMA; HUMAN; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT; STROKE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK FACTORS; STENTS; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 79851505717     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.11.001     Document Type: Article

References (18)

1. Sideris S.K., Bonios M.J., and Eftihiadis E.E. Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation Hellenic J Cardiol 46 2005 242 246 (Pubitemid 41664062)
2. Bovill E.G., Terrin M.L., and Stump D.C. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial Ann Intern Med 115 1991 256 265
3. Merlini P.A., Rossi M., and Menozzi A. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting Circulation 109 2004 2203 2206 (Pubitemid 38625397)
4. Salengro E., Mulvihill N.T., and Farah B. Acute profound thrombocytopenia after use of eptifibatide for coronary stenting Catheter Cardiovasc Interv 58 2003 73 75 (Pubitemid 36055305)
5. Kereiakes D.J., Berkowitz S.D., and Lincoff A.M. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade Am Heart J 140 2000 74 80 (Pubitemid 30471244)
6. Makoni S.N. Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature Heart 86 2001 E18
7. McClure M.W., Berkowitz S.D., and Sparapani R.R. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience Circulation 99 1999 2892 2900 (Pubitemid 29258977)
8. Nagge J., Jackevicius C., and Dzavik V.D. Acute profound thrombocytopenia associated with eptifibatide therapy Pharmacotherapy 23 2003 374 379 (Pubitemid 36259342)
9. Harrington R.A., Sane D.C., and Califf R.M. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction study group J Am Coll Cardiol 23 1994 891 898 (Pubitemid 24090874)
10. Manor S.M., Guillory G.S., and Jain S.P. Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting Pharmacotherapy 24 2004 664 667 (Pubitemid 38585961)
11. Best P.J., Mathew V., and Markovic S.N. Clopidogrel-associated autoimmune thrombocytopenic purpura Catheter Cardiovasc Interv 62 2004 339 340 (Pubitemid 38868870)
12. Nikolsky E., Sadeghi H.M., and Effron M.B. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction Am J Cardiol 96 2005 474 481 (Pubitemid 41132760)
13. Berkowitz S.D., Sane D.C., and Sigmon K.N. Occurrence and clinical significance of thrombocytopenia in a population undergoing high risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) study group J Am Coll Cardiol 32 1998 311 319 (Pubitemid 28396477)
14. Lincoff A.M., Bittl J.A., and Harrington R.A. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863 (Pubitemid 37430344)
15. Stone G.W., Bertrand M.E., and Moses J.W. ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY trial JAMA 297 2007 591 602
16. Stone G.W., McLaurin B.T., and Cox D.A. Bivalirudin for patients with acute coronary syndromes. The HORIZONS-AMI N Engl J Med 355 2006 2203 2216 (Pubitemid 44791162)
17. Cutlip D.E., Windecker S., and Mehran R. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
18. Wang T.Y., Ou F.S., and Roe M.T. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice (sub-analysis of the CRUSADE registry) Circulation 119 2009 2454 2462